Spectrum Pharmaceuticals Inc. (SPPI) and Orgenesis Inc. (NASDAQ:ORGS) Comparison side by side

We are contrasting Spectrum Pharmaceuticals Inc. (NASDAQ:SPPI) and Orgenesis Inc. (NASDAQ:ORGS) on their analyst recommendations, institutional ownership, profitability, risk, dividends, earnings and valuation. They both are Biotechnology companies, competing one another.

Valuation and Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Spectrum Pharmaceuticals Inc. 109.33M 7.51 140.66M -1.16 0.00
Orgenesis Inc. 18.66M 3.71 19.18M -1.40 0.00

We can see in table 1 the earnings per share (EPS), top-line revenue and valuation of Spectrum Pharmaceuticals Inc. and Orgenesis Inc.

Profitability

Table 2 shows us Spectrum Pharmaceuticals Inc. and Orgenesis Inc.’s return on equity, net margins and return on assets.

Net Margins Return on Equity Return on Assets
Spectrum Pharmaceuticals Inc. -128.66% 0% 0%
Orgenesis Inc. -102.79% 0% 0%

Volatility & Risk

Spectrum Pharmaceuticals Inc. has a 2.53 beta, while its volatility is 153.00%, thus making it more volatile than Standard and Poor’s 500. Orgenesis Inc.’s 1.3 beta is the reason why it is 30.00% more volatile than Standard and Poor’s 500.

Analyst Recommendations

Spectrum Pharmaceuticals Inc. and Orgenesis Inc. Ratings and Recommendations are available on the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Spectrum Pharmaceuticals Inc. 0 0 3 3.00
Orgenesis Inc. 0 0 0 0.00

Spectrum Pharmaceuticals Inc.’s upside potential is 257.99% at a $26.67 average price target.

Institutional and Insider Ownership

The shares of both Spectrum Pharmaceuticals Inc. and Orgenesis Inc. are owned by institutional investors at 79.7% and 2.8% respectively. About 1.1% of Spectrum Pharmaceuticals Inc.’s share are owned by insiders. On the other hand, insiders owned about 26.45% of Orgenesis Inc.’s shares.

Performance

In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Spectrum Pharmaceuticals Inc. -8.21% -12.36% -26.23% -35.22% -51.47% -0.34%
Orgenesis Inc. 0% -6.64% -7.6% -23.47% -46.62% -3.85%

For the past year Spectrum Pharmaceuticals Inc. was less bearish than Orgenesis Inc.

Summary

Spectrum Pharmaceuticals Inc. beats on 6 of the 9 factors Orgenesis Inc.

Spectrum Pharmaceuticals, Inc. develops and commercializes oncology and hematology drug products. The company markets six drug products, including FUSILEV for patients with metastatic colorectal cancer and rescue after high-dose methotrexate therapy in osteosarcoma, and to diminish toxicity and counteract the effects of impaired methotrexate elimination and of inadvertent overdosage of folic acid antagonists; FOLOTYN, a folate analogue metabolic inhibitor to treat patients with relapsed or refractory PTCL; ZEVALIN injection for patients with follicular non-HodgkinÂ’s lymphoma; MARQIBO, a sphingomyelin/cholesterol liposome-encapsulated formulation for adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia; BELEODAQ injection for patients with relapsed or refractory PTCL; and EVOMELA for use as a conditioning treatment prior to autologous stem cell transplant in multiple myeloma patients. It is also developing ROLONTIS for chemotherapy-induced neutropenia; QAPZOLA for intravesical instillation in post-transurethral resection of bladder tumors in patients with non-muscle invasive bladder cancer; and POZIOTINIB for treating breast and lung cancer. The company sells its drugs through a direct sales force in the United States; and through distributors in Europe. Spectrum Pharmaceuticals, Inc. has licensing and development agreement with Cell Therapeutics, Inc.; license agreement with Merck & Cie AG, Sloan-Kettering Institute, and Cydex Pharmaceuticals, Inc.; development and commercialization collaboration agreement with Allergan, Inc.; collaboration agreement with Nippon Kayaku Co., LTD.; licensing and collaboration agreement with Onxeo DK; and co-development and commercialization agreement with Hanmi Pharmaceutical Company. The company was formerly known as NeoTherapeutics, Inc. and changed its name to Spectrum Pharmaceuticals, Inc. in December 2002. Spectrum Pharmaceuticals, Inc. was founded in 1987 and is headquartered in Henderson, Nevada.

Orgenesis Inc., a biopharmaceutical company, develops trans-differentiation technologies in the field of cell therapy and regenerative medicine. The company's Contract Development and Manufacturing Organization segment specializes in cell therapy development for advanced medicinal products. This segment provides process and assay development services; and GMP contract manufacturing services. Its Cellular Therapy Business segment develops cell trans-differentiation technology induce shift in the developmental fate of cells from the liver and differentiating them into pancreatic beta cell-like insulin-producing cells for patients with diabetes. Orgenesis Inc. has a collaboration agreement with Biosequel LLC to carry out clinical trials and market its products in Russia, Belarus, and Kazakhstan. The company was formerly known as Business Outsourcing Services, Inc. and changed its name to Orgenesis Inc. in August 2011. Orgenesis Inc. was founded in 2008 and is based in Germantown, Maryland.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.